Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2023, 5(2); doi: 10.25236/FMSR.2023.050201.

Research on PAR-1 in Cancer, Cardiovascular Disease and Nerve-related Diseases


Mengli Li, Zhiguang Zhao

Corresponding Author:
Zhiguang Zhao

Department of Clinical Pathology, the Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, China


PAR-1 (protein kinase receptor 1, also known as thrombin receptor) is a member of the G protein-coupled receptor family, and its main ligand is thrombin. PAR-1 is mainly expressed in platelets, endothelial cells, smooth muscle cells and some neural cells, involved in hemostasis and atherosclerosis formation. At present, a great deal of research has also confirmed that PAR-1 is involved in epithelial-to-mesenchymal transition and epithelial-to-endothelial transformation; PAR-1 can regulate the NF-κB pathway, stimulate the formation of tumor angiogenesis, and participate in the development of tumors through a variety of ways. At the same time, the blood state of tumor patients often presents a hypercoagulable state. As one of the thrombin receptors, PAR-1 may participate in the formation of hypercoagulable state in tumor patients. The review focuses on the expression and activation mechanism of PAR-1 and its physiological pathological process; And how to participate in the occurrence and development of tumors and the relationship with cardiovascular diseases. The aim is to point out that PAR-1 may be a potential target for tumor therapy and may be helpful to improve the hypercoagulable state and prolong the survival of patients with advanced cancer.


PAR-1; EMT; high blood coagulation; atherosclerosis; tumor angiogenesis and metastasis; nervous system

Cite This Paper

Mengli Li, Zhiguang Zhao. Research on PAR-1 in Cancer, Cardiovascular Disease and Nerve-related Diseases. Frontiers in Medical Science Research (2023) Vol. 5, Issue 2: 1-8. https://doi.org/10.25236/FMSR.2023.050201.


[1] Zhou M, Wang H, Zeng X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017[J].The Lancet,2019, 394 (10204): 1145-1158.

[2] Kobiyama K, Ley K.Atherosclerosis[J]. Circ Res,2018, 123 (10): 1118-1120.

[3] Alberelli M A, De Candia E. Functional role of protease activated receptors in vascular biology[J]. Vascul Pharmacol, 2014, 62 (2): 72-81.

[4] Flaumenhaft R, De Ceunynck K.Targeting PAR1: Now What?[J]. Trends Pharmacol Sci, 2017, 38 (8): 701-716.

[5] Zhang C, Srinivasan Y, Arlow D H, et al.High-resolution crystal structure of human protease-activated receptor 1[J]. Nature,2012, 492 (7429): 387-92.

[6] Krupnick J G, Benovic J L. The role of receptor kinases and arrestins in G protein-coupled receptor regulation[J]. Annu Rev Pharmacol Toxicol, 1998, 38: 289-319.

[7] Trejo J.Protease-activated receptors: new concepts in regulation of G protein-coupled receptor signaling and trafficking[J]. J Pharmacol Exp Ther, 2003, 307 (2): 437-42.

[8] Ferguson S S.Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling[J]. Pharmacol Rev, 2001, 53 (1): 1-24.

[9] Schmid S L, Mcniven M A, De Camilli P.Dynamin and its partners: a progress report[J].Curr Opin Cell Biol, 1998, 10 (4): 504-12.

[10] Tsao P, Cao T, Von Zastrow M.Role of endocytosis in mediating downregulation of G-protein-coupled receptors[J].Trends Pharmacol Sci, 2001, 22 (2): 91-6.

[11] Coughlin S R. Thrombin signalling and protease-activated receptors[J]. Nature, 2000, 407 (6801): 258-64.

[12] Connolly A J, Ishihara H, Kahn M L, et al.Role of the thrombin receptor in development and evidence for a second receptor[J]. Nature, 1996, 381 (6582): 516-9.

[13] Riewald M, Petrovan R J, Donner A, et al.Activation of endothelial cell protease activated receptor 1 by the protein C pathway[J]. Science,2002, 296 (5574): 1880-2.

[14] Nelken N A, Soifer S J, O'keefe J, et al.Thrombin receptor expression in normal and atherosclerotic human arteries[J]. J Clin Invest,1992, 90 (4): 1614-21.

[15] Schechter N M, Brass L F, Lavker R M, et al. Reaction of mast cell proteases tryptase and chymase with protease activated receptors (PARs) on keratinocytes and fibroblasts[J]. J Cell Physiol, 1998, 176 (2): 365-73.

[16] Libby P, Aikawa M.Stabilization of atherosclerotic plaques: new mechanisms and clinical targets[J]. Nat Med,2002, 8 (11): 1257-62.

[17] Leger A J, Covic L, Kuliopulos A.Protease-activated receptors in cardiovascular diseases[J]. Circulation, 2006, 114 (10): 1070-7.

[18] Poole R M, Elkinson S.Vorapaxar: first global approval[J]. Drugs,2014, 74 (10): 1153-63.

[19] Ishida Y, Nagai A, Kobayashi S, et al.Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase[J].J Neuropathol Exp Neurol,2006, 65 (1): 66-77.

[20] Cui J L X W H L W. Antagonism of Protease-Activated Receptor 4 Protects Against Traumatic Brain Injury by Suppressing Neuroinflammation via Inhibition of Tab2_NF-κB Signaling.pdf[J]. 2021.

[21] Price R, Ferrari E, Gardoni F, et al.Protease-activated receptor 1 (PAR1) inhibits synaptic NMDARs in mouse nigral dopaminergic neurons[J].Pharmacol Res,2020, 160: 105185.

[22] Gonzalez J, Jurado-Coronel J C, Ávila M F, et al.NMDARs in neurological diseases: a potential therapeutic target[J].Int J Neurosci,2015, 125 (5): 315-27.

[23] Löschmann P A, De Groote C, Smith L, et al.Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease[J].Exp Neurol,2004, 187 (1): 86-93.

[24] Pompili E, Fabrizi C, Somma F, et al.PAR1 activation affects the neurotrophic properties of Schwann cells[J].Mol Cell Neurosci,2017, 79: 23-33.

[25] Junge C E, Sugawara T, Mannaioni G, et al.The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia[J].Proc Natl Acad Sci U S A,2003, 100 (22): 13019-24.

[26] Vaughan P J, Pike C J, Cotman C W, et al.Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults[J].J Neurosci,1995, 15 (7 Pt 2): 5389-401.

[27] Katoh M, Katoh M.WNT signaling pathway and stem cell signaling network[J].Clin Cancer Res,2007, 13 (14): 4042-5.

[28] Naumov G N, Nilsson M B, Cascone T, et al.Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance[J].Clin Cancer Res,2009, 15 (10): 3484-94.

[29] Zhao B, Wu M, Hu Z, et al.Thrombin is a therapeutic target for non-small-cell lung cancer to inhibit vasculogenic mimicry formation[J].Signal Transduct Target Ther,2020, 5 (1): 117.

[30] Xiao T, Zhang Q, Zong S, et al.Protease-activated receptor-1 (PAR1) promotes epithelial-endothelial transition through Twist1 in hepatocellular carcinoma[J].J Exp Clin Cancer Res,2018, 37 (1): 185.

[31] Wang Y, Liao R, Chen X, et al.Twist-mediated PAR1 induction is required for breast cancer progression and metastasis by inhibiting Hippo pathway[J].Cell Death Dis,2020, 11 (7): 520.

[32] Folkman J.Tumor angiogenesis: therapeutic implications[J].N Engl J Med,1971, 285 (21): 1182-6.

[33] Fernandez A, Udagawa T, Schwesinger C, et al.Angiogenic potential of prostate carcinoma cells overexpressing bcl-2[J].J Natl Cancer Inst,2001, 93 (3): 208-13.

[34] Quintero-Fabián S, Arreola R, Becerril-Villanueva E, et al.Role of Matrix Metalloproteinases in Angiogenesis and Cancer[J].Front Oncol,2019, 9: 1370.

[35] Carmeliet P, Jain R K.Molecular mechanisms and clinical applications of angiogenesis[J].Nature,2011, 473 (7347): 298-307.

[36] Li S, Xu H X, Wu C T, et al.Angiogenesis in pancreatic cancer: current research status and clinical implications[J].Angiogenesis,2019, 22 (1): 15-36.

[37] Nassar E, Hassan N, El-Ghonaimy E A, et al.Syndecan-1 Promotes Angiogenesis in Triple-Negative Breast Cancer through the Prognostically Relevant Tissue Factor Pathway and Additional Angiogenic Routes[J].Cancers (Basel),2021, 13 (10).

[38] Hernández N A, Correa E, Avila E P, et al.PAR1 is selectively over expressed in high grade breast cancer patients: a cohort study[J].J Transl Med,2009, 7: 47.

[39] Elste A P, Petersen I.Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer[J].J Mol Histol,2010, 41 (2-3): 89-99.

[40] Caunt M, Huang Y Q, Brooks P C, et al.Thrombin induces neoangiogenesis in the chick chorioallantoic membrane[J].J Thromb Haemost,2003, 1 (10): 2097-102.

[41] Liu L, Yan B, Yang Z, et al.ncRuPAR inhibits gastric cancer progression by down-regulating protease-activated receptor-1[J].Tumour Biol,2014, 35 (8): 7821-9.

[42] Braeuer R R, Zigler M, Villares G J, et al.Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment[J].Semin Cancer Biol,2011, 21 (2): 83-8.

[43] Ma L, Perini R, Mcknight W, et al.Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets[J].Proc Natl Acad Sci U S A,2005, 102 (1): 216-20.

[44] Kessenbrock K, Plaks V, Werb Z.Matrix metalloproteinases: regulators of the tumor microenvironment[J].Cell,2010, 141 (1): 52-67.

[45] Boire A, Covic L, Agarwal A, et al.PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells[J].Cell,2005, 120 (3): 303-13.

[46] Fujimoto D, Hirono Y, Goi T, et al.The activation of proteinase-activated receptor-1 (PAR1) promotes gastric cancer cell alteration of cellular morphology related to cell motility and invasion[J].Int J Oncol,2013, 42 (2): 565-73.

[47] Yang E, Boire A, Agarwal A, et al.Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis[J].Cancer Res,2009, 69 (15): 6223-31.

[48] Mcdonald J A, Khodyakova A, Aranjuez G, et al.PAR-1 kinase regulates epithelial detachment and directional protrusion of migrating border cells[J].Curr Biol,2008, 18 (21): 1659-67.

[49] Reed C E, Kita H.The role of protease activation of inflammation in allergic respiratory diseases[J].J Allergy Clin Immunol,2004, 114 (5): 997-1008; quiz 1009.

[50] Vasan N, Baselga J, Hyman D M.A view on drug resistance in cancer[J].Nature,2019, 575 (7782): 299-309.

[51] Sharma P, Hu-Lieskovan S, Wargo J A, et al.Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy[J].Cell,2017, 168 (4): 707-723.

[52] Queiroz K C, Shi K, Duitman J, et al.Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance[J].Int J Cancer,2014, 135 (10): 2294-304.

[53] Zheng X, Turkowski K, Mora J, et al.Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy[J].Oncotarget,2017, 8 (29): 48436-48452.

[54] Tantivejkul K, Loberg R D, Mawocha S C, et al.PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism[J].J Cell Biochem,2005, 96 (3): 641-52.

[55] Suzuki T, Moraes T J, Vachon E, et al.Proteinase-activated receptor-1 mediates elastase-induced apoptosis of human lung epithelial cells[J].Am J Respir Cell Mol Biol,2005, 33 (3): 231-47.

[56] Chin A C, Vergnolle N, Macnaughton W K, et al.Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability[J].Proc Natl Acad Sci U S A,2003, 100 (19): 11104-9.

[57] Blom J W, Doggen C J, Osanto S, et al.Malignancies, prothrombotic mutations, and the risk of venous thrombosis[J].Jama,2005, 293 (6): 715-22.

[58] Qian W, Tao L, Wang Y, et al.Downregulation of Integrins in Cancer Cells and Anti-Platelet Properties Are Involved in Holothurian Glycosaminoglycan-Mediated Disruption of the Interaction of Cancer Cells and Platelets in Hematogenous Metastasis[J].J Vasc Res,2015, 52 (3): 197-209.

[59] Nierodzik M L, Karpatkin S.Thrombin induces tumor growth, metastasis, and angiogenesis: Evidence for a thrombin-regulated dormant tumor phenotype[J].Cancer Cell,2006, 10 (5): 355-62.

[60] Zacharski L R, Henderson W G, Rickles F R, et al.Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75[J].Cancer,1984, 53 (10): 2046-52.

[61] Furie B, Furie B C.Mechanisms of thrombus formation[J].N Engl J Med,2008, 359 (9): 938-49.

[62] Kahn M L, Zheng Y W, Huang W, et al.A dual thrombin receptor system for platelet activation[J].Nature,1998, 394 (6694): 690-4.

[63] Kahn M L, Nakanishi-Matsui M, Shapiro M J, et al.Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin[J].J Clin Invest,1999, 103 (6): 879-87.

[64] Gnanenthiran S R, Pennings G J, Reddel C J, et al.Identification of a Distinct Platelet Phenotype in the Elderly: ADP Hypersensitivity Coexists With Platelet PAR (Protease-Activated Receptor)-1 and PAR-4-Mediated Thrombin Resistance[J].Arterioscler Thromb Vasc Biol,2022, 42 (8): 960-972.

[65] Jiang L, Xu C, Yu S, et al.A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation[J].J Thromb Haemost,2013, 11 (5): 930-40.

[66] De Meis E, Azambuja D, Ayres-Silva J P, et al.Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma[J].Braz J Med Biol Res,2010, 43 (4): 403-8.

[67] Momi S, Falcinelli E, Petito E, et al.Matrix metalloproteinase-2 on activated platelets triggers endothelial PAR-1 initiating atherosclerosis[J].Eur Heart J,2022, 43 (6): 504-514.

[68] Pan Y, Wangqin R, Li H, et al.F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA[J].Neurology,2021, 96 (1): e1-e9.

[69] Walsh S W, Strauss J F, 3rd.Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?[J].Am J Obstet Gynecol,2022, 226 (2s): S945-s953.

[70] Palumbo J S.Crosstalk between hemostasis and immunity in cancer pathogenesis[J].Thromb Res,2022, 213 Suppl 1: S3-s7.

[71] Schweickert P G, Yang Y, White E E, et al.Thrombin-PAR1 signaling in pancreatic cancer promotes an immunosuppressive microenvironment[J].J Thromb Haemost,2021, 19 (1): 161-172.

[72] Ungar L, Rodriguez F, Mahaffey K W.Vorapaxar: emerging evidence and clinical questions in a new era of PAR-1 inhibition[J].Coron Artery Dis,2016, 27 (7): 604-15.

[73] Frampton J E.Vorapaxar: a review of its use in the long-term secondary prevention of atherothrombotic events[J].Drugs,2015, 75 (7): 797-808.

[74] Battinelli E M, Markens B A, Kulenthirarajan R A, et al.Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response[J].Blood,2014, 123 (1): 101-12.

[75] Reddel C J, Allen J D, Ehteda A, et al.Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent[J].J Thromb Haemost,2017, 15 (3): 477-486.

[76] Yokota N, Zarpellon A, Chakrabarty S, et al.Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice[J].J Thromb Haemost,2014, 12 (1): 71-81.

[77] Zhao B, Wu M, Hu Z, et al.A novel oncotherapy strategy: Direct thrombin inhibitors suppress progression, dissemination and spontaneous metastasis in non-small cell lung cancer[J].Br J Pharmacol,2022, 179 (22): 5056-5073.